Skip to main content
. 2018 May 1;8(5):879–891.

Figure 1.

Figure 1

Treatment schedule. Peripheral blood from allogenic donor was drawn on day 1 and NK cells were infused intravenously on days 13 to 15. New sample of peripheral blood for the second course was drawn on day 16 and NK cells were infused intravenously on days 28-30. Cetuximab was administered intravenously on day 13 and the weekly maintenance dose was continued until tumor progression or unacceptable toxicity occurred.